JOHNSON & JOHNSON is 107.0x more valuable than Cogent Biosciences, Inc. by market capitalization ($573.98 B vs $5.36 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | COGT | JNJ |
|---|---|---|
| Market cap | $5.36 B | $573.98 B |
| US-listed rank | #1334 | #20 |
| Revenue (latest FY) | - | $94.19B |
| Net income (latest FY) | -$328.94M | $26.80B |
| Net margin | - | 28.5% |
| P/E (trailing FY) | - | 21.4 |
| SEC filings | 595 | 984 |
JOHNSON & JOHNSON is 107.0x more valuable than Cogent Biosciences, Inc. by market capitalization ($573.98 B vs $5.36 B).
Full pages: Cogent Biosciences, Inc. and JOHNSON & JOHNSON, or browse the full rankings.